title: Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
abstract: The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meeting for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, SGLT-2 inhibitors, acarbose and insulins. Diabetologists' and cardiologists' perspective on the potential need of new study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presentations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, which will be held from 20-22 October 2016 in Munich ( http://www.dcvd.org).
authors.affiliation: Forschergruppe Diabetes e.V, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, Neuherberg, 85764, Munich, Germany. oliver.schnell@lrz.uni-muenchen.de.
authors.forename: Oliver
authors.initials: O
authors.lastname: Schnell
authors.affiliation: Forschergruppe Diabetes e.V, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, Neuherberg, 85764, Munich, Germany. eberhard.standl@lrz.uni-muenchen.de.
authors.forename: Eberhard
authors.initials: E
authors.lastname: Standl
authors.affiliation: Internal Medicine Department, Clinical County Emergency Hospital Constanta, Tomis Blvd. No. 145, 900591, Constanta, Romania. dcatrinoiu@gmail.com.
authors.forename: Doina
authors.initials: D
authors.lastname: Catrinoiu
authors.affiliation: Diabetes and Metabolic Disease Unit, IRCCS MultiMedica, Via Milanese 300, 20099, Sesto San Giovanni, MI, Italy. stefano.genovese@multimedica.it.
authors.forename: Stefano
authors.initials: S
authors.lastname: Genovese
authors.affiliation: Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 13, Belgrade, 11000, Serbia. lalic.nm@gmail.com.
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Lalic
authors.affiliation: 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, 128 08, Prague 2, Czech Republic. jan.skrha@lf1.cuni.cz.
authors.forename: Jan
authors.initials: J
authors.lastname: Skra
authors.affiliation: Department of Endocrinology Diabetology Nutrition, Hôpital Jean VERDIER, Paris 13 University, CINFO, CRNH-IdF, Avenue du 14 Juillet, 93140, Bondy, France. paul.valensi@noos.fr.
authors.forename: Paul
authors.initials: P
authors.lastname: Valensi
authors.affiliation: Institut d'Investigacions Biomèdiques August Pi I Sunyer-IDIBAPS, Mallorca, 183, 08036, Barcelona, Spain. ACERIELL@clinic.ub.es.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ceriello
mesh_terms: D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000379:methods; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D012107:Research Design; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents